Answers are grounded in this paper and cite their sources.
Case report reveals recurrent severe cutaneous adverse reactions to fluoroquinolones and rifampicin in an HIV patient, highlighting the need for cautious sequential rechallenge.
We report a 47-year-old human immunodeficiency virus-positive male with disseminated tuberculosis who developed recurrent maculopapular eruptions with mucosal involvement following exposure to multiple drugs, including diclofenac, rifampicin, and fluoroquinolones. Sequential drug rechallenge strongly implicated fluoroquinolones and rifampicin. He was successfully managed with systemic corticosteroids, intravenous immunoglobulin, and careful sequential reintroduction of nonculprit anti-tubercular therapy drugs. This case highlights the importance of drug reintroduction and cautious use of fluoroquinolones and rifampicin in immunocompromised patients.
No takes yet. Share an insight, caveat, or question.
Chamariya et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: